Deep Intelligent Pharma
Category: AI in Biotech / Drug Discovery
AI-native pharmaceutical R&D platform using multi-agent generative AI to accelerate clinical trial design, execution, and drug discovery. Deep Intelligent Pharma was founded in 2017. The company is led by Xing Li (Hygeia Li). Based in Singapore. Team size: 101-500. Total funding raised: $165M. Latest round: Series D. Key investors include HongShan (Sequoia China / 红杉中国), CDH Investments (鼎晖百孚 / Dinghui Baifu), ZhenFund (真格基金), CITIC Capital (中信), Trustar Capital (信宸资本), Jinyi Capital (金镒资本), Kaitai Capital (凯泰资本), Xin Ding / NewDing Capital (新鼎资本), Loongson Capital.
- Founded
- 2017
- Headquarters
- Singapore
- Team size
- 101-500
- Total funding
- $165M
Value proposition
Compresses drug development timelines (up to 50x faster clinical operations monitoring, 12x faster protocol design) using AI multi-agent 'digital workforce' that automates clinical trial workflows end-to-end, from indication selection to CSR report generation.
Products and solutions
AI CRO 6.0 (AI-driven clinical research platform), Molecular Design Engine (drug discovery platform), Agent Matrix (multi-agent orchestration system, deployed since 2023), Digital Rehearsal (end-to-end clinical trial simulation)
Unique value
Combines large-scale AI models with scientific computing to compress molecule screening-to-candidate cycles from years to weeks; multi-agent 'bionic workforce' operates 24/7 replacing traditional CRO human-labor bottlenecks
Target customer
Pharmaceutical and biotech companies running clinical trials and drug R&D programs globally
Industries served
Pharmaceutical R&D, Clinical Trials/CRO, Biotech, also expanding into Materials Science (agrochemicals, batteries, semiconductors, alloys)
Technology advantage
Proprietary multi-agent AI system (six coordinated agents) covering protocol design, data collection, statistical analysis, and medical writing; mechanism-driven (MoA-based) AI reasoning rather than brute-force screening; zero-defect PMDA (Japan regulator) consultation track record
How they differentiate
Focuses on full clinical trial workflow automation (not just preclinical drug discovery) via a proprietary multi-agent system, and cross-applies its AI mechanism-driven approach to materials science (batteries, semiconductors, agrochemicals) beyond pure pharma
Main competitors
XtalPi, Insilico Medicine, Recursion Pharmaceuticals
Key partnerships
Microsoft Azure (AI platform collaboration, Microsoft Build 2025), PMDA (Japan regulator, zero-defect consultation track record), Harbour BioMed (Global AI+ alliance participant), Imbioray Bio / 英百瑞 (strategic partnership on ACC-NK AI platform, ~¥300M collaboration intention, 2026)
Major milestones
2017: Founded by AI scientist from multinational pharma, 2018: Expanded into Japan market (regulatory bridgehead), 2021: Achieved commercialization/profitability, 2023: Deployed multi-agent 'Agent Matrix', 2025-12: Series D ~$50M led by CDH Baifu (HongShan/Xin Ding), unicorn valuation, 2026-02/03: Follow-on ~$60M then ~$40M (Trustar/Jinyi/Kaitai/CDH/Xinding); ~$150M raised in ~3 months across Series D series
Growth metrics
1,500+ cumulative signed clients; 16% market share in LLM/agent-driven clinical CRO services (Frost & Sullivan 2026); claims up to 50x speed improvement in clinical operations monitoring and 12x in protocol design
Market positioning
Positioned as a leading AI-native pharma R&D/CRO platform in China/APAC, cited by Frost & Sullivan as holding ~16% market share of the LLM/agent-driven clinical CRO services market; called a 'global AI science unicorn' post Series D
Geographic focus
China, Japan, and global (US/EU) markets; strong Japan regulatory (PMDA) presence
About Xing Li (Hygeia Li)
12+ years new-drug development at multinational pharma (Pfizer, Sanofi, Johnson & Johnson); former J&J China new-drug development leadership team member; led J&J's first APAC AI project (neural-network regulatory translation engine); degree from Peking University School of Pharmaceutical Sciences (药学院).
Latest news about Deep Intelligent Pharma
- Deep Intelligent Pharma raised nearly 50 million USD in Series D financing to scale its AI-native clinical trial engine. Utilizing a bionic ecosystem of 10,000 atomic agents, the platform achieves 99.
- Deep Intelligent Pharma has secured nearly US$50 million in Series D funding to revolutionize clinical trials with its multi-agent AI platform. This investment will accelerate the development of an AI
More AI in Biotech / Drug Discovery companies
Official website: https://dipgroup.com/
